UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 28, 2015
Commission File Number |
Exact name of registrant as principal office and address |
State of incorporation or organization |
I.R.S. Employer Identification No. | |||
001-36887 | Warner Chilcott Limited Cannons Court 22 Victoria Street Hamilton HM 12 Bermuda (441) 295-2244 |
Bermuda | 98-0496358 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 7.01 | Regulation FD Disclosure. |
On September 28, 2015, Allergan plc (the Company), of which Warner Chilcott Limited is a consolidated subsidiary, issued a press release announcing its updated second-half 2015 continuing operations financial forecast. The Company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K filed on September 30, 2015. A copy of the press release is incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended (the Exchange Act), or as otherwise subject to liability of that section, nor shall such information be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit |
Description of Exhibit | |
Exhibit 99.1 | Allergan plc Press Release dated September 28, 2015 (incorporated by reference to Exhibit 99.1 to the Allergan plc Current Report on Form 8-K, filed with the SEC on September 30, 2015). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 30, 2015 |
WARNER CHILCOTT LIMITED | |||||
By: | /s/ A. Robert D. Bailey | |||||
Name: | A. Robert D. Bailey | |||||
Title: | Secretary |
Exhibit Index
Exhibit |
Description of Exhibit | |
Exhibit 99.1 | Allergan plc Press Release dated September 28, 2015 (incorporated by reference to Exhibit 99.1 to the Allergan plc Current Report on Form 8-K, filed with the SEC on September 30, 2015). |